Table 1.
Immune checkpoint inhibitor-induced colitis (irAE) n = 18 | Ulcerative colitis (UC)n = 9 | P value | ||
---|---|---|---|---|
Age, years | Median (range) | 66.5 (43 to 79) | 23.0 (14 to 49) | <0.001 |
Gender | Male | 13 (72.2%) | 3 (33.3%) | 1.000 |
Female | 5 (27.8%) | 6 (66.6%) | ||
Geboes score grade | Grade 1 | 3 (16.7%) | 1 (11.1%) | 0.426 |
Grade 2 | 9 (50.0%) | 2 (22.2%) | ||
Grade 3 | 1 (5.6%) | 1 (11.1%) | ||
Grade 4 | 5 (27.8%) | 5 (55.6%) | ||
Colitis activity | Mild | 9 (50.0%) | 1 (11.1%) | 0.059 |
Moderate | 7 (38.9%) | 4 (44.4%) | ||
Severe | 2 (11.1%) | 4 (44.4%) | ||
Cancer types | Lung | 11 (61.1%) | – | – |
Stomach | 2 (11.1%) | – | ||
Kidney | 3 (16.7%) | – | ||
Ovary | 1 (5.6%) | – | ||
Unknown | 1 (5.6%) | – | ||
Availability of inactive tissue | Yes | 14 (77.8%) | 9 (100%) | – |
No | 4 (22.2%) | 0 (0%) | ||
Availability of active tissue | Yes | 15 (83.3%) | 9 (100%) | – |
No | 3 (16.7%) | 0 (0%) |
*P values were based on the Fisher’s exact test for categorical data and the Mann-Whitney U test for continuous data.